TROP2 Expression and Pancreatic Cancer Prognosis
Author Information
Author(s): Fong D, Moser P, Krammel C, Gostner J M, Margreiter R, Mitterer M, Gastl G, Spizzo G
Primary Institution: Innsbruck Medical University
Hypothesis
High expression of TROP2 correlates with poor prognosis in pancreatic cancer.
Conclusion
TROP2 overexpression is significantly associated with decreased overall survival in pancreatic cancer patients.
Supporting Evidence
- TROP2 overexpression was observed in 55% of pancreatic cancer patients.
- TROP2 overexpression significantly correlated with poor overall survival.
- Patients with TROP2 overexpression had a median overall survival of 8 months compared to 14 months for those without.
Takeaway
This study found that a protein called TROP2 is found in high amounts in many pancreatic cancer patients, and having more of it means a person is likely to live for a shorter time.
Methodology
The study used immunohistochemistry to analyze TROP2 expression in tissue samples from 197 patients with pancreatic adenocarcinoma and assessed survival using Kaplan–Meier curves and Cox regression models.
Limitations
The study is retrospective and may not account for all variables affecting survival.
Participant Demographics
Patients diagnosed with pancreatic ductal adenocarcinoma between 1990 and 2006, with a mean age of 65.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website